Stem cell populations employ cell-intrinsic and niche-mediated mechanisms to preserve long-term self-renewal and regenerative potential. We propose that tumor-initiating cells (TICs) hijack this developmental circuitry to sustain their growth and establish an early immunosuppressive microenvironment during malignant progression. Recent work implicates CXCR4 tissue-resident macrophages (TRMs) in the mammary gland as a central orchestrator of this process. Conserved CXCL12/CXCR4-AKT-β-catenin signaling links CXCR4 TRM support of normal mammary stem cells to TIC maintenance, underscoring how developmental niches are exploited in malignancy. During tumorigenesis, aberrant CXCL12 production from tumor-associated fibroblasts promotes the expansion of CXCR4 TRMs, while CXCR4 signaling enhances ALDH1A2-dependent retinoic acid production, which induces regulatory T cells and thereby suppresses anti-tumor immunity at the earliest stages of tumor development. From this perspective, early immune evasion is not only a hallmark of cancer but also a therapeutic window. Targeting TRMs early in cancer development could delay, or even prevent, malignant initiation. More broadly, we propose that TIC-niche crosstalk constitutes a tractable vulnerability, and that incorporating TRM-directed interventions alongside conventional and immune-based therapies may shift the balance toward durable tumor control.